Patents by Inventor Yuan Mi

Yuan Mi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190233426
    Abstract: A compound of Formula (IA), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a PRC2-mediated disease or disorder: wherein A, R3, R4, R6, and R7 are as defined herein.
    Type: Application
    Filed: June 9, 2017
    Publication date: August 1, 2019
    Inventors: Ho Man CHAN, Xingnian Fu, Xiang-Ju Justin Gu, Ying HUANG, Ling LI, Yuan MI, Wei QI, Martin SENDZIK, Yongfeng SUN, Long WANG, Zhengtian YU, Hailong ZHANG, Ji Yue ZHANG, Man ZHANG, Qiong ZHANG, Kehao ZHAO
  • Publication number: 20190202828
    Abstract: A compound of Formula (IA), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a PRC2-mediated disease or disorder: wherein A, R6, R7 and R8 are as defined herein.
    Type: Application
    Filed: June 6, 2017
    Publication date: July 4, 2019
    Inventors: Ho Man CHAN, Xingnian Fu, Xiang-Ju Justin Gu, Ying HUANG, Ling LI, Yuan MI, Wei QI, Martin SENDZIK, Yongfeng SUN, Long WANG, Zhengtian YU, Hailong ZHANG, Ji Yue ZHANG, Man ZHANG, Qiong ZHANG, Kehao ZHAO
  • Publication number: 20190142837
    Abstract: A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a PRC2-mediated disease or disorder: wherein R1, R2, R3, R4, R5, and n are as defined herein.
    Type: Application
    Filed: January 11, 2019
    Publication date: May 16, 2019
    Inventors: Ho Man CHAN, Xiang-Ju Justin GU, Ying HUANG, Ling LI, Yuan MI, Wei QI, Martin SENDZIK, Yongfeng SUN, Long WANG, Zhengtian YU, Hailong ZHANG, Ji Yue (Jeff) ZHANG, Man ZHANG, Qiong ZHANG, Kehao ZHAO
  • Patent number: 10220036
    Abstract: A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a PRC2-mediated disease or disorder: wherein R1, R2, R3, R4, R5, and n are as defined herein.
    Type: Grant
    Filed: December 21, 2015
    Date of Patent: March 5, 2019
    Assignee: Novartis AG
    Inventors: Ho Man Chan, Xiang-Ju Justin Gu, Ying Huang, Ling Li, Yuan Mi, Wei Qi, Martin Sendzik, Yongfeng Sun, Long Wang, Zhengtian Yu, Hailong Zhang, Ji Yue (Jeff) Zhang, Man Zhang, Qiong Zhang, Kehao Zhao
  • Publication number: 20170348312
    Abstract: A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a PRC2-mediated disease or disorder: wherein R1, R2, R3, R4, R5, and n are as defined herein.
    Type: Application
    Filed: December 21, 2015
    Publication date: December 7, 2017
    Inventors: Ho Man CHAN, Xiang-Ju Justin GU, Ying HUANG, Ling LI, Yuan MI, Wei QI, Martin SENDZIK, Yongfeng SUN, Long WANG, Zhengtian YU, Hailong ZHANG, Ji Yue (Jeff) ZHANG, Man ZHANG, Qiong ZHANG, Kehao ZHAO
  • Patent number: 9580437
    Abstract: A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a PRC2-mediated disease or disorder: wherein R1, R2, R3, R4, R5, and n are as defined herein.
    Type: Grant
    Filed: December 21, 2015
    Date of Patent: February 28, 2017
    Assignee: Novartis AG
    Inventors: Ho Man Chan, Xiang-Ju Justin Gu, Ying Huang, Ling Li, Yuan Mi, Wei Qi, Martin Sendzik, Yongfeng Sun, Long Wang, Zhengtian Yu, Hailong Zhang, Ji Yue (Jeff) Zhang, Man Zhang, Qiong Zhang, Kehao Zhao
  • Patent number: 9474762
    Abstract: The invention relates to compounds of formula (I) and salts thereof: wherein the substituents are as defined in the specification; a compound of formula (I) for use in the treatment of the human or animal body, in particular with regard to c-Met tyrosine kinase mediated diseases or conditions; the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases; pharmaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner, and processes for the preparation of a compound of formula (I).
    Type: Grant
    Filed: May 19, 2015
    Date of Patent: October 25, 2016
    Assignee: NOVARTIS AG
    Inventors: Chao Chen, Haibing Deng, Haibing Guo, Feng He, Lei Jiang, Fang Liang, Yuan Mi, Huixin Wan, Yao-Chang Xu, Hongping Yu, Ji Yue Zhang
  • Publication number: 20160176882
    Abstract: A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a PRC2-mediated disease or disorder: wherein R1, R2, R3, R4, R5, and n are as defined herein.
    Type: Application
    Filed: December 21, 2015
    Publication date: June 23, 2016
    Inventors: Ho Man CHAN, Xiang-Ju Justin GU, Ying HUANG, Ling LI, Yuan MI, Wei QI, Martin SENDZIK, Yongfeng SUN, Long WANG, Zhengtian YU, Hailong ZHANG, Ji Yue (Jeff) ZHANG, Man ZHANG, Qiong ZHANG, Kehao ZHAO
  • Publication number: 20150250799
    Abstract: The invention relates to compounds of formula (I) and salts thereof: wherein the substituents are as defined in the specification; a compound of formula (I) for use in the treatment of the human or animal body, in particular with regard to c-Met tyrosine kinase mediated diseases or conditions; the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases; pharmaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner, and processes for the preparation of a compound of formula (I).
    Type: Application
    Filed: May 19, 2015
    Publication date: September 10, 2015
    Applicant: Novartis AG
    Inventors: Chao CHEN, Haibing DENG, Haibing Guo, Feng HE, Lei Jiang, Fang Liang, Yuan Mi, Huixin Wan, Yao-Chang Xu, Hongping Yu, Ji Yue Zhang
  • Patent number: 9062045
    Abstract: The invention relates to compounds of formula (I) and salts thereof: wherein the substituents are as defined in the specification; a compound of formula (I) for use in the treatment of the human or animal body, in particular with regard to c-Met tyrosine kinase mediated diseases or conditions; the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases; pharmaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner, and processes for the preparation of a compound of formula (I).
    Type: Grant
    Filed: September 13, 2012
    Date of Patent: June 23, 2015
    Assignee: Novartis AG
    Inventors: Chao Chen, Haibing Deng, Haibing Guo, Feng He, Lei Jiang, Fang Liang, Yuan Mi, Huixin Wan, Yao-Chang Xu, Hongping Yu, Ji Yue (Jeff) Zhang
  • Publication number: 20130324526
    Abstract: The invention relates to compounds of formula (I) and salts thereof: wherein the substituents are as defined in the specification; a compound of formula (I) for use in the treatment of the human or animal body, in particular with regard to c-Met tyrosine kinase mediated diseases or conditions; the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases; pharmaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner, and processes for the preparation of a compound of formula (I).
    Type: Application
    Filed: February 8, 2012
    Publication date: December 5, 2013
    Applicant: NOVARTIS AG
    Inventors: Feng He, Haibing Deng, Xingnian Fu, Haibing Guo, Yuan Mi, Xiaoxia Yan, Hongping Yu, Ji Yue (Jeff) Zhang
  • Publication number: 20130245002
    Abstract: The invention relates to compounds of formula (I) and salts thereof: wherein the substituents are as defined in the specification; a compound of formula (I) for use in the treatment of the human or animal body, in particular with regard to c-Met tyrosine kinase mediated diseases or conditions; the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases; pharmaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner, and processes for the preparation of a compound of formula (I).
    Type: Application
    Filed: September 13, 2012
    Publication date: September 19, 2013
    Applicant: NOVARTIS AG
    Inventors: Chao CHEN, Haibing DENG, Haibing GUO, Feng HE, Lei JIANG, Fang LIANG, Yuan MI, Huixin WAN, Yao-Chang XU, Hongping YU, Ji Yue ZHANG
  • Patent number: 8507676
    Abstract: The invention relates to compounds of formula (I) and salts thereof: wherein the substituents are as defined in the specification; a compound of formula (I) for use in the treatment of the human or animal body, in particular with regard to c-Met tyrosine kinase mediated diseases or conditions; the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases; pharmaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner, and processes for the preparation of a compound of formula (I).
    Type: Grant
    Filed: August 6, 2012
    Date of Patent: August 13, 2013
    Assignee: Novartis AG
    Inventors: Miao Dai, Xingnian Fu, Feng He, Lei Jiang, Yue Li, Fang Liang, Lei Liu, Yuan Mi, Yao-Chang Xu, Guoliang Xun, Xiaoxia Yan, Zhengtian Yu, Ji Yue Zhang
  • Patent number: 8497368
    Abstract: The invention relates to compounds of formula (I) and salts thereof: wherein the substituents are as defined in the specification; a compound of formula (I) for use in the treatment of the human or animal body, in particular with regard to c-Met tyrosine kinase mediated diseases or conditions; the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases; pharmaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner, and processes for the preparation of a compound of formula (I).
    Type: Grant
    Filed: August 10, 2010
    Date of Patent: July 30, 2013
    Assignee: Novartis AG
    Inventors: Feng He, Miao Dai, Xingnian Fu, Yue Li, Lei Liu, Yuan Mi, Yao-chang Xu, Guoliang Xun, Zhengtian Yu, Ji Yue Zhang
  • Patent number: 8410264
    Abstract: The invention relates to compounds of formula (I) and salts thereof: wherein the substituents are as defined in the specification; a compound of formula (I) for use in the treatment of the human or animal body, in particular with regard to c-Met tyrosine kinase mediated diseases or conditions; the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases; pharmaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner, and processes for the preparation of a compound of formula (I).
    Type: Grant
    Filed: August 19, 2010
    Date of Patent: April 2, 2013
    Assignee: Novartis AG
    Inventors: Miao Dai, Xingnian Fu, Feng He, Lei Jiang, Yue Li, Fang Liang, Lei Liu, Yuan Mi, Yao-chang Xu, Guoliang Xun, Xiaoxia Yan, Zhengtian Yu, Ji Yue Zhang
  • Publication number: 20120302570
    Abstract: The invention relates to compounds of formula (I) and salts thereof: wherein the substituents are as defined in the specification; a compound of formula (I) for use in the treatment of the human or animal body, in particular with regard to c-Met tyrosine kinase mediated diseases or conditions; the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases; pharmaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner, and processes for the preparation of a compound of formula (I).
    Type: Application
    Filed: August 6, 2012
    Publication date: November 29, 2012
    Applicant: NOVARTIS AG
    Inventors: Miao DAI, Xingnian FU, Feng HE, Lei JIANG, Yue LI, Fang LIANG, Lei LIU, Yuan MI, Yao-Chang XU, Guoliang XUN, Xiaoxia YAN, Zhengtian YU, Ji Yue ZHANG
  • Publication number: 20120142681
    Abstract: The invention relates to compounds of formula (I) and salts thereof: wherein the substituents are as defined in the specification; a compound of formula (I) for use in the treatment of the human or animal body, in particular with regard to c-Met tyrosine kinase mediated diseases or conditions; the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases; pharmaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner, and processes for the preparation of a compound of formula (I).
    Type: Application
    Filed: August 10, 2010
    Publication date: June 7, 2012
    Applicant: NOVARTIS AG
    Inventors: Feng He, Miao Dai, Xingnian Fu, Yue Li, Lei Liu, Yuan Mi, Yao-chang Xu, Guoliang Xun, Zhengtian Yu, Ji Yue Zhang
  • Patent number: D659129
    Type: Grant
    Filed: October 14, 2011
    Date of Patent: May 8, 2012
    Assignee: Cheng Uei Precision Industry Co., Ltd.
    Inventors: Shih-Yuan Mi, Jia-Hung Su, Kai Shih
  • Patent number: D670276
    Type: Grant
    Filed: December 21, 2011
    Date of Patent: November 6, 2012
    Assignee: Cheng Uei Precision Industry Co., Ltd.
    Inventors: Shih-Yuan Mi, Yi-Ru Yang, Jia-Hung Su, Kai Shih
  • Patent number: D671097
    Type: Grant
    Filed: December 21, 2011
    Date of Patent: November 20, 2012
    Assignee: Cheng Uei Precision Industry Co., Ltd.
    Inventors: Shih-Yuan Mi, Yi-Ru Yang, Jia-Hung Su, Kai Shih